InvaplexAR-Detox and dmLT Adjuvant in the Netherlands and Zambia
Conditions: Shigellosis; Bacillary Dysentery Interventions: Biological: 2.5 μg InvaplexAR-Detox; Biological: 2.5 μg InvaplexAR-Detox with 0.1 μg of dmLT; Biological: 10 μg InvaplexAR-Detox; Biological: 10 μg InvaplexAR-Detox with 0.1 μg of dmLT; Biological: Placebo Sponsors: Leiden University Medical Center; Centre for Infectious Disease Research in Zambia; PATH; Walter Reed Army Institute of Research (WRAIR); Göteborg University; European Vaccine Initiative; European and Developing Countries Clinical Trials Partnership (EDCTP) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Clinical Trials | Dysentery | Netherlands Health | Partnerships | Research | Zambia Health